MSH6 and central nervous system cancer: MSH6 mutation status (wild type or mutant) was also assessed because mutations are frequently seen in high-grade gliomas that recur after treatment with TMZ and RT, and because MSH6 mutations are known to mediate TMZ resistance [30–32].